← All stocks

Aquestive Therapeutics, Inc.

AQST Balanced
CIK 0001398733 #3023 in the set updated 17 Sep 2026
Bought (120 mo)
$3.13M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$5.88M
$1.80M on a plan · $955.67K straight out of an exercise
Sold at will
$3.12M
17 of 35 sales
Net
−$2.75M
+$12.38K against sales at will

By person

23 insiders · 72 transactions
4.7×

Daniel Barber holds only 4.7 times base salary in stock. $3.14M of shares against $659.89K in salary for 2025.

Salary from the company's own proxy. The shares are what Daniel Barber last reported holding, valued at $4.82, the price Common Stock was last bought or sold at on the open market here, on 15 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
BRATTON DOUGLAS K
10% owner
$2.48M (1)
+$2.48M
2,161,004
1.72%
$10.41M
−43.0%
Barber Daniel
President and CEO
$104.05K (3)
$1.77M (9) scheduled
−$1.67M
652,317
0.5197%
$3.14M
+714.7%
Schobel Alexander Mark
Chief Innovation/Tech Officer
$79.45K (4)
$1.62M (9)
−$1.54M
984,476
0.7844%
$4.74M
−2.4%
Jung Cassie
Chief Operating Officer
$975.90K (4) scheduled
−$975.90K
208,833
0.1664%
$1.01M
+502.6%
Boyd Peter E.
Chief People Officer
$13.53K (5)
$336.91K (4) scheduled
−$323.38K
284,024
0.2263%
$1.37M
+472.0%
TOTH A ERNEST JR
Chief Financial Officer
$243.09K (1)
−$243.09K
283,460
0.2258%
$1.37M
Kraus Carl N
Chief Medical Officer
$141.90K (1) scheduled
−$141.90K
282,475
0.2251%
$1.36M
Kendall Keith J
CEO and President
$121.18K (9)
$255.31K (1)
−$134.13K
639,149
0.5092%
$3.08M
+4.4%
Krop Julie
Director
$125.39K (1) scheduled
−$125.39K
0
0.0000%
$0.00
Maxwell John T.
SVP-Chief Financial Officer
$142.35K (2)
$24.00K (1)
+$118.35K
150,614
0.1200%
$725.88K
+8.7%
Korczynski Sherry
Chief Commercial Officer
$111.36K (2)
−$111.36K
235,689
0.1878%
$1.14M
+371.4%
Cioffi Melina
SVP, Regulatory Affairs
$105.62K (1)
−$105.62K
273,200
0.2177%
$1.32M
+49.9%
Scibetta James S
Director
$86.98K (3)
+$86.98K
31,635
0.0252%
$152.46K
+265.1%
BRAENDER LORI J
Corporate Secretary
$86.15K (4)
$167.35K (1)
−$81.19K
231,042
0.1841%
$1.11M
Marshall Ken W.
SVP, Chief Commercial Officer
$14.67K (1)
+$14.67K
151,445
0.1207%
$729.89K
Wood Theresa
SVP-HR and Org. Development
$9.16K (2)
+$9.16K
80,765
0.0643%
$389.25K
+1.9%
Wargacki Stephen
Chief Science Officer
343,552
0.2737%
$1.66M
+1,722%
Zalewski Thomas A.
Chief Legal Officer
100,000
0.0797%
$481.95K
Davis Matthew W.
Chief Development Officer
100,000
0.0797%
$481.95K
Cochran John
Director
99,486
0.0793%
$479.47K
+32.5%
BROWN GREGORY B
Director
75,085
0.0598%
$361.87K
0.0%
Greenhawt Matthew J.
Chief Medical Officer
75,000
0.0598%
$361.46K
COSTA SANTO J
Director
17,327
0.0138%
$83.51K
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
Korczynski Sherry
9 Sep 2026
Chief Commercial Officer
Sold after exercise
8,750
$5.22
$45.68K
Krop Julie
23 Jun 2026
Director
Sold after exercise
25,000
$5.02
$125.39K
Jung Cassie
15 Oct 2025
Chief Operating Officer
Sold after exercise
67,575
$7.01
$473.70K
Jung Cassie
4 Sep 2025
Chief Operating Officer
Sold after exercise
62,180
$5.00
$310.90K

What was left out

Form 4 filings counted 282
Amendments (4/A) skipped 8
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 14
Sales straight out of an exercise 4
Sales at will 17
Transactions with no price 0
Shares from compensation/vesting 11,683,907
Sales filed before the plan box existed 9
History held since 26 Jul 2018